<DOC>
	<DOCNO>NCT02230969</DOCNO>
	<brief_summary>The primary objective study determine incidence serious adverse event ( SAEs ) participant relapse form multiple sclerosis ( MS ) routine clinical practice ass overall long-term clinical effectiveness Plegridy participant relapse form MS routine clinical practice . The secondary objective study study population describe Plegridy prescription utilization adherence pattern routine clinical practice ; ass specific long-term clinical effectiveness Plegridy participant relapse form MS routine clinical practice ; monitor safety tolerability Plegridy routine clinical practice assess incidence adverse event ( AEs ) flu-like symptom ( FLS ) , injection site reaction ( ISRs ) , AEs ( include laboratory abnormality ) lead treatment discontinuation ; assess effect FLS participant-reported effectiveness , satisfaction , prophylactic management use FLS-Visual Analog Scale ( FLS-VAS ) ; evaluate change health-related quality life ( HRQoL ) , FLS , FLS-VAS , healthcare resource consumption , treatment adherence time .</brief_summary>
	<brief_title>Plegridy Observational Program</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Key Patient MS newly , currently , prescribe Plegridy accord local label include patient participate Study 105MS302 ( NCT01332019 ) Study 105MS303 ( NCT01939002 ) . Patient willing able complete patientreported outcome ( PRO ) minimal assistance . Key Concurrent enrollment clinical trial investigational product . Participation noninterventional study allow long participation interfere protocol likely affect subject 's ability comply protocol . NOTE : Other protocol define Inclusion/Exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>peginterferon</keyword>
	<keyword>relapse</keyword>
	<keyword>pegylated</keyword>
	<keyword>Subcutaneous</keyword>
	<keyword>Injectable</keyword>
	<keyword>Multiple Sclerosis</keyword>
</DOC>